Myriad Genetics Issues Inaugural Environmental, Social and Governance Report
June 28 2022 - 4:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today released its first environmental,
social and governance (ESG) report, highlighting increased efforts
to support a healthy, equitable and sustainable society. The report
outlines actions taken to expand access to genetic testing, advance
social justice, and increase environmental sustainability.
“For more than 31 years, Myriad Genetics has worked to be a
force for good in the world as we fulfill our mission to advance
health and well-being for all. In our inaugural ESG report, we seek
to convey our core values as a caring, ethical, and sustainable
company committed to continuous improvement,” said Paul J. Diaz,
president and CEO, Myriad Genetics. “I want to thank our 2,400
teammates for the progress we have made to date, recognizing we
have more work to be done. We are committed to intensifying our ESG
focus helping to address the needs of the patients, healthcare
providers, stakeholders, and communities we serve.”
Key highlights from the report include:
- Increasing affordable access to genetic
testing. In 2021, Myriad Genetics provided more than $49
million in financial assistance to 86,000+ uninsured and
underinsured patients, offering financial assistance, free testing,
and payment options to those in need.
- Supporting underserved patient populations. In
2021, Myriad launched the newest version of its market-leading
MyRisk™ Hereditary Cancer Test with RiskScore® which, for the first
time offers women of all ancestries a personalized polygenic breast
cancer risk assessment. In 2022, as part of its new suite of
Precise™ Oncology Solutions, Myriad launched the Precise Treatment
Registry, a secure cloud-based database designed to advance
equitable care and accelerate collaborative cancer research by
enabling any physician to analyze diverse, de-identified patient
data involving ancestry, geography, diagnosis and treatment
outcomes. Additionally, Myriad’s Prequel® Prenatal Screen with
AMPLIFY technology allows women with high body mass index (BMI) to
gain access to this non-invasive prenatal screening protocol which
uses cell-free DNA to determine if a pregnancy is at an increased
risk for common chromosomal abnormalities.
- Embracing diversity, equity and inclusion.
Myriad Genetics is committed to recruiting, hiring and promoting
team members from diverse backgrounds. At the end of 2021, women
made up 61% of the Myriad workforce, 40% of leadership roles, and
33% of the Board of Directors. The company also announced founding
support for the development of a genetic counseling program at
Xavier University of Louisiana, one of the country’s leading
historically black universities.
- Advancing sustainability. Myriad has recycled
nearly 70 tons of plastic from its Salt Lake City laboratory since
2019. The new Myriad Support Center in Salt Lake City is designed
with environmentally friendly features including a 495-kilowatt
photovoltaic solar energy system that provides electricity for
portions of the campus, conserving energy and cost. The company is
also starting construction on a new LEED certified Silver research
and innovation center in South Francisco and a new molecular
diagnostics lab in Salt Lake City. These state-of-the-art
facilities will reflect the latest advancements in scalable modular
design, including automated liquid handling, reduced waste volume,
and lower use of plastics.
To view Myriad’s 2021 ESG Report in full, click here.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and
commercializes genetic tests that help assess the risk of
developing disease or disease progression and guide treatment
decisions across medical specialties where genetic insights can
significantly improve patient care and lower healthcare costs. Fast
Company named Myriad among the World’s Most Innovative Companies
for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx,
Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary
Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify,
Foresight, Precise, FirstGene, Health.Illuminated., RiskScore,
Prolaris, GeneSight, and EndoPredict are trademarks or registered
trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc.
All rights reserved.
Safe Harbor Statement This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements that the company’s new facilities will reflect the
latest advancements in scalable modular design, including automated
liquid handling, reduced waste volume, and lower use of plastics.
These “forward-looking statements” are management’s present
expectations of future events and are subject to a number of risks,
uncertainties, assumptions, and other factors that could cause
actual results to differ materially and adversely from those
described in the forward-looking statements. Such factors include
those risks described in the company’s filings with the U.S.
Securities and Exchange Commission, including the company’s Annual
Report on Form 10-K filed on February 25, 2022, as well as any
updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K.
Media
Contact: |
Investor Contact: |
Megan Manzari |
Nathan Smith |
(385) 318-3718 |
(801) 505-5067 |
Megan.Manzari@myriad.com |
Nathan.Smith@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024